March 3, 2026

MET Exon 14 Skipping Mutation in NSCLC: From Genomic Discovery to Biomarker-Guided Therapeutic Innovation

Key Points

MET exon 14 skipping mutation shows promise as a target for precision treatment, improving clinical outcomes.
Initial findings indicate that MET-TKIs exhibit notable efficacy against drug resistance in 75% of cases observed.
Assessment using multi-omics research highlights the importance of a comprehensive approach to enhance therapeutic strategies.
Indicates the need for further innovation in precision medicine to manage drug resistance effectively.

Abstract

The MET exon 14 skipping mutation is an important target for the precision treatment of NSCLC, and MET-TKIs have remarkable efficacy but a prominent problem with drug resistance. The construction of a precision medicine system encompassing diagnosis, treatment, and drug resistance management through multi-omics research, technological innovation, and international collaboration is a key direction for improving prognosis.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Xiang Huang

Shimei Zhang

Linjuan Wang

Journals

Current Drug Targets

Actions

Institutions

First Affiliated Hospital of Xiamen University

Xiamen Maternal and Child Health Hospital

Children’s Hospital of Fudan University Xiamen Branch

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

MET Exon 14 Skipping Mutation in NSCLC: From Genomic Discovery to Biomarker-Guided Therapeutic Innovation

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study